Skip to content

Study · In vitro (cells) · 2022

7 results

Brilacidin, a Non-Peptide Defensin-Mimetic Molecule, Inhibits SARS-CoV-2 Infection by Blocking Viral Entry.

Xu C, Wang A, Honnen W, Pinter A, Weston WK, Harness JA, Narayanan A, Chang TL

EC microbiology8 Mar 2022Cited by 14 (Europe PMC)

PMID35695877 (opens in a new tab)PMCIDPMC9186380 (opens in a new tab)PepBankPUB-35695877
Source linkPubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Activity measurement

    In cells, brilacidin blocked SARS-CoV-2 infection.

    In plain wordsIn cells, brilacidin blocked SARS-CoV-2 infection.

    Peptide
    Brilacidin
    Outcome
    DecreaseSARS-CoV-2 infection
    Study

    n: not reported in source

    Outcome group
    Antiviral activity · Infection
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Brilacidin blocked SARS-CoV-2 infection but had no effect after viral entry.
  2. 02LabIn vitro (cells)Activity measurement

    In cells, brilacidin had no effect after viral entry.

    In plain wordsIn cells, brilacidin had no effect after viral entry.

    Peptide
    Brilacidin
    Outcome
    No significant changePost-entry activity
    Study

    n: not reported in source

    Outcome group
    Antiviral activity · Infection
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Brilacidin blocked SARS-CoV-2 infection but had no effect after viral entry.
  3. 03LabIn vitro (cells)Activity measurement

    In cells, brilacidin inhibited pseudotyped SARS-CoV-2 virus expressing the P.1 Brazil strain spike protein.

    In plain wordsIn cells, brilacidin inhibited pseudovirus with the P.1 Brazil strain spike protein.

    Peptide
    Brilacidin
    Outcome
    DecreaseP.1 pseudovirus inhibition
    Study

    n: not reported in source

    Outcome group
    Antiviral activity · Infection
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Brilacidin inhibited pseudotyped SARS-CoV-2 viruses expressing spike proteins from the P.1 Brazil strain and the B.1.1.7 UK strain.
  4. 04LabIn vitro (cells)Activity measurement

    In cells, brilacidin inhibited pseudotyped SARS-CoV-2 virus expressing the B.1.1.7 UK strain spike protein.

    In plain wordsIn cells, brilacidin inhibited pseudovirus with the B.1.1.7 UK strain spike protein.

    Peptide
    Brilacidin
    Outcome
    DecreaseB.1.1.7 pseudovirus inhibition
    Study

    n: not reported in source

    Outcome group
    Antiviral activity · Infection
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Brilacidin inhibited pseudotyped SARS-CoV-2 viruses expressing spike proteins from the P.1 Brazil strain and the B.1.1.7 UK strain.
  5. 05LabIn vitro (cells)Mechanism

    In cells, brilacidin affected viral attachment through concentration-dependent hACE2-dependent and independent mechanisms.

    In plain wordsIn cells, brilacidin affected viral attachment through mechanisms that depended on concentration and could involve hACE2.

    Peptide
    Brilacidin
    Outcome
    Direction not reportedViral attachment
    Study

    n: not reported in source

    Outcome group
    Antiviral activity · Infection
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Brilacidin affected viral attachment in hACE2-dependent and independent manners depending on the concentrations.
  6. 06LabIn vitro (cells)Mechanism

    In lab tests, brilacidin entry inhibition did not involve blocking spike receptor-binding domain binding to hACE2.

    In plain wordsIn lab tests, brilacidin did not inhibit entry by blocking spike receptor-binding domain binding to hACE2.

    Peptide
    Brilacidin
    Outcome
    Not applicableSpike receptor-binding domain binding to hACE2
    Study

    n: not reported in source

    Outcome group
    Antiviral activity · Infection
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The inhibitory effect on viral entry was not mediated through blocking the binding of either the spike receptor-binding domain or the spike S1 protein to hACE2 proteins.
  7. 07LabIn vitro (cells)Mechanism

    In lab tests, brilacidin entry inhibition did not involve blocking spike S1 binding to hACE2.

    In plain wordsIn lab tests, brilacidin did not inhibit entry by blocking spike S1 binding to hACE2.

    Peptide
    Brilacidin
    Outcome
    Not applicableSpike S1 binding to hACE2
    Study

    n: not reported in source

    Outcome group
    Antiviral activity · Infection
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The inhibitory effect on viral entry was not mediated through blocking the binding of either the spike receptor-binding domain or the spike S1 protein to hACE2 proteins.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.